Our analysis of several publicly available mRNA expression data sets [32–34] revealed that ATAD2 is significantly overexpressed in patient-derived ovarian cancer samples (Fig. 1A, B) as compared to normal ovary tissue samples. Here, ATAD2 is linked to ovarian cancer.